HOME >> MEDICINE >> NEWS
FDA approves new labelling for Seroquel in bioplar mania

Alderley Park, UK — 23 July, 2004 -- AstraZeneca announced today that the U.S. Food and Drug Administration (FDA) has approved additional efficacy labelling information based on 12-week data for SEROQUEL (quetiapine), a psychotropic medication indicated for the treatment of acute manic episodes associated with bipolar I disorder. The data 1, part of the large scale effort to examine SEROQUEL's use in bipolar disorder, showed that after 12 weeks, approximately two-thirds of patients receiving SEROQUEL alone experienced significant improvement in manic symptoms and achieved remission .

SEROQUEL is the first medication in its class to include monotherapy safety and efficacy data for acute manic episodes associated with bipolar disorder extending beyond three weeks in its label.

"For patients with bipolar disorder and their clinicians, it's important to know that Seroquel is not only effective in reducing symptoms of acute mania the first few weeks, but is also effective in the subsequent continuation phase, when patients can still have significant symptoms and are still at risk for relapsing," said Jamie Mullen, MD, Senior Director of Clinical Research, AstraZeneca. "These data demonstrate that SEROQUEL treatment alone works early and continues to work through 12 weeks. For patients coping with this illness, this is good news."

SEROQUEL was originally approved by the FDA in January 2004 as a monotherapy and adjunct therapy with lithium or divalproex, for the short-term treatment of acute manic episodes associated with bipolar I disorder. This approval was based on efficacy results following three weeks of treatment. These trials showed SEROQUEL to be well-tolerated and effective in the treatment of manic episodes — excited mental states seen in bipolar disorder that are characterized by impulsive behaviour, racing thoughts, pressured speech, and decreased need for sleep. 1, 2.

SEROQUEL has received
'"/>

Contact: Rupert Doggett
rupert.doggett@shirehealthinternational.com
44-207-471-1512
Shire Health International
23-Jul-2004


Page: 1 2 3

Related medicine news :

1. FDA approves Pfizers Lyrica for the treatment of the two most common forms of neuropathic pain
2. FDA approves Enablex for treatment of overactive bladder
3. FDA approves Fosrenol(R) in end-stage renal disease (ESRD) patients
4. FDA approves Adderall XR (R) to treat ADHD in adults
5. FDA approves EPZICOM
6. FDA approves Enbrel to treat psoriasis
7. FDA approves Climara Pro to treat menopause symptoms
8. FDA approves new approach to schizophrenia treatment
9. FDA approves new HIV protease inhibitor, Lexiva (TM)
10. FDA approves Wellbutrin XL(TM)
11. FDA approves Baxters ADVATE for the treatment of hemophilia A

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: FDA approves new labelling for Seroquel bioplar mania

(Date:5/25/2013)... NY (PRWEB) May 25, 2013 On May ... many people do not wish to discuss or plan for ... life. FuneralFinancials.com released a Must-Do List to ... 1. Funeral Financials recommends, “Creating a personal fact sheet.” , ... to organize financial information and personal data. It may ...
(Date:5/25/2013)... New York,NY (PRWEB) May 25, 2013 ... SizeItUp officially declared the integration of the 2012 ... Lamborghini Aventador is the latest entrant in the list ... Designed intelligently, the vehicle is all set to thrill ... with vicious acceleration power and spectacular looks, the 2012 ...
(Date:5/25/2013)... Many orthodontists have thought about moving their office to ... Most people would naturally assume that the company ... service and support would own and maintain all the ... be wrong. Cloud providers lease space in a ... houses servers and related equipment to run cloud environments) ...
(Date:5/25/2013)... Plains, NJ (PRWEB) May 25, 2013 ... iPhone. The universal app version of Word Hunt ... app versions of Concentration, Edge Match, Flash 2, Sudoku and ... , The brain games’ gameplay and revolutionary lifetime brain fitness ... 4 inch displays. , “100 years of brain fitness measurement ...
(Date:5/25/2013)... (PRWEB) May 25, 2013 Prairie ... community, is hosting an American Red Cross Blood Drive ... , The community, which is located at 955 Villa ... incomes, including those on Medicaid, who need some help ... Gift of Life," says Andrea Arview Frey, Director of ...
Breaking Medicine News(10 mins):Health News:FuneralFinancials.com Releases Last Wishes Must-Do List 2Health News:Rim Fitments Provider SizeItUp Launches The Database Integration For The 2012 Lamborghini Aventador 2Health News:Cirrus Ortho Launches Cloud Computing for Orthodontic Industry That is Unlike Any Other 2Health News:Acuity Games Apps Come to the iPhone 2Health News:Carbondale Affordable Assisted Living Community to Host Red Cross Blood Drive 2
(Date:5/24/2013)... -- In accordance with Rule 17.1 and Rule 2.9 of ... States Exchange Act, Echo Pharma Acquisition Limited ("Royalty Pharma") today ... ELN). Background On 2 May 2013, ... the entire of the issued and to be issued share ... On 20 May 2013, Royalty Pharma announced the ...
(Date:5/23/2013)... SHENYANG, CHINA , May 24, 2013 /PRNewswire/ ... ("3SBio" or the "Company"), a leading ... developing, manufacturing and marketing biopharmaceutical products, announced today ... (the "EGM"), the Company,s shareholders voted in favor ... previously announced agreement and plan of merger dated ...
(Date:5/23/2013)... Amgen (NASDAQ: AMGN ) will present ... on Thursday, May 30, 2013, at the Westin Boston Waterfront ... Eastern Daylight Time. Arvind Sood , vice ... conference. Live audio of the presentation can be accessed from ... Investors. A replay of the webcast will also be available ...
Breaking Medicine Technology:Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 2Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 3Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 4Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 5Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 6Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 7Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 8Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 93SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 23SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 3
Cached News: